Deep research and expert guides on maintaining your visual health.
Bleb-Forming Microshunts (PreserFlo) vs XEN Gel Stents: 2025 Review The PreserFlo™ MicroShunt and XEN® Gel Stent are minimally invasive glaucoma surgery (MIGS) implants that create a subconjunctival drainage bleb, bridging between traditional trabeculectomy and ab interno angle procedures. These devices aim to lower intraocular pressure (IOP) in moderate-to-advanced glaucoma with fewer complicatio...
AI for Glaucoma Detection and Prognosis: Performance, Bias, and Clinical Integration in 2025 Glaucoma is a leading cause of irreversible blindness, affecting over 90 million people worldwide (pmc.ncbi.nlm.nih.gov). Worryingly, more than 70% of glaucoma cases remain undiagnosed (pmc.ncbi.nlm.nih.gov). Early detection is crucial because vision loss from glaucoma cannot be undone. In recent years, a...
24-Hour IOP Monitoring: Emerging Home and Implantable Technologies Glaucoma management is poised for a transformation as novel 24-hour intraocular pressure (IOP) monitoring tools come into practice. Traditional office IOP checks miss the nocturnal and early-morning spikes that many patients experience (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In 2025, home-accessible rebound tonometers, cont...
Introduction Visual field testing (perimetry) remains indispensable in glaucoma and neuro-ophthalmic care. For decades the Humphrey Field Analyzer (HFA) has been the clinical standard (pmc.ncbi.nlm.nih.gov), but its bulky hardware and lengthy exams limit accessibility – issues highlighted during the COVID-19 pandemic. Virtual reality (VR) headsets and home-based platforms promise more flexible te...
Introduction Visual field testing (perimetry) remains indispensable in glaucoma and neuro-ophthalmic care. For decades the Humphrey Field Analyzer (HFA) has been the clinical standard (pmc.ncbi.nlm.nih.gov), but its bulky hardware and lengthy exams limit accessibility – issues highlighted during the COVID-19 pandemic. Virtual reality (VR) headsets and home-based platforms promise more flexible te...
Autophagy and Glaucoma: Rethinking Neuroprotection Glaucoma is an optic neuropathy marked by progressive death of retinal ganglion cells (RGCs) and their axons, leading to irreversible vision loss (pmc.ncbi.nlm.nih.gov). Traditionally managed by lowering intraocular pressure (IOP), glaucoma is also now recognized as a neurodegenerative disease. By the time visual field defects emerge, substant...
Caffeine, L-Theanine, and IOP in Glaucoma Glaucoma patients often wonder whether common stimulants or supplements might affect their eye pressure (intraocular pressure, IOP). Caffeine – a central nervous system stimulant found in coffee, tea and energy drinks – can transiently raise blood pressure and may influence IOP. By contrast, L-theanine (an amino acid abundant in green tea) is known for c...
Curcumin for Neuroinflammation in Glaucoma: Mechanisms and Formulations Glaucoma is a progressive optic neuropathy marked by retinal ganglion cell (RGC) loss and vision field deficits. In addition to elevated intraocular pressure (IOP), oxidative stress and neuroinflammation are important contributors to RGC degeneration (pmc.ncbi.nlm.nih.gov). Curcumin, the bioactive polyphenol from turmeric, e...
Resveratrol and Sirtuin Activation: Can Caloric Restriction Mimetics Protect the Optic Nerve? Glaucoma is a progressive optic neuropathy characterized by the loss of retinal ganglion cells (RGCs) and optic nerve damage, leading to irreversible vision loss. Standard treatments lower intraocular pressure (IOP), but many patients continue to decline, spurring interest in neuroprotection. One emergi...
Stacking Strategies for Glaucoma Neuroprotection Glaucoma is a progressive optic neuropathy characterized by retinal ganglion cell (RGC) apoptosis that leads to irreversible vision loss. Beyond elevated intraocular pressure (IOP), factors such as oxidative stress, mitochondrial dysfunction, excitotoxicity, and neuroinflammation drive glaucomatous damage (pmc.ncbi.nlm.nih.gov). While lowering IOP...
